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Abstract 
 
Mitochondria are the cellular powerhouses, fuelling metabolic processes 
through their generation of ATP. However we now recognise that these 
organelles also have pivotal roles in the generation of reactive oxygen species 
(ROS) and the regulation of cell death, inflammation and metabolism. 
Mitochondrial dysfunction therefore leads to oxidative stress, cell death, 
inflammation and altered metabolism, which are all key processes in 
atherosclerosis. Recent evidence indicates that mitochondrial DNA (mtDNA) 
damage is present and promotes atherosclerosis through mitochondrial 
dysfunction. In this review we discuss the role and mechanisms linking 
mtDNA damage and atherosclerosis, and identify areas of mitochondrial 
biology that may yield potential therapeutic targets.  
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Abbreviations 
 
AMPK  AMP activated protein kinase 
cGAS  cyclic GMP-AMP synthase 
DAMP  damage-associated molecular pattern 
Drp1  dynamin-related protein 1 
FGF21 fibroblast growth factor 21 
IFN  interferon 
MOMP mitochondrial outer membrane permeabilisation 
MPTP  mitochondrial permeability transition pore 
mtDNA mitochondrial DNA 
NFκβ  nuclear factor kappa beta 
Opa1  optic atrophy 1 
PAMP  pathogen-associated molecular pattern 
ROS  reactive oxygen species 
STING stimulator of interferon genes 
TFAM  mitochondrial transcription factor A 
TLR  toll-like receptor 
TRAIL  tumour necrosis factor-related apoptosis-inducing ligand 
VSMC  vascular smooth muscle cell 
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Article 
Atherosclerosis- a mitochondrial disease? 
Whilst significant advances in medical and surgical treatment have been 
made, atherosclerosis remains the leading cause of death in the western 
world. Atherosclerosis is characterised by fatty plaque formation in the 
arteries- the large conduit vessels carrying vital oxygen and nutrients to the 
tissues. These plaques can rupture, potentially leading to vessel occlusion 
and clinical sequelae such as heart attacks and strokes [1]. With such an 
impact on health, the need remains to characterise the underlying 
pathological processes and to find new therapeutic targets. Recent work 
highlights that mitochondrial DNA (mtDNA) damage and dysfunction promote 
atherosclerosis and thus opens new avenues for therapeutic interventions.  
 
The atherosclerotic plaque forms at sites of endothelial dysfunction, often 
where there is disturbed flow and altered shear stress [2]. Circulating lipids 
are taken up into the vessel intima, thereby initiating the early lesion- the fatty 
streak. The lipids undergo oxidative modification by enzymes and reactive 
oxygen species (ROS), promoting endothelial dysfunction. The expression of 
endothelial adhesion molecules recruits monocytes, where they become 
macrophages that engulf lipids to form foam cells. Whilst the scavenging of 
oxidised lipids is initially protective, an inflammatory response is triggered, 
leading to cell death and the development of the plaque necrotic core. 
Vascular smooth muscle cells (VSMCs) proliferate and/or migrate to the 
intima, where they secrete the collagen and extra-cellular matrix that forms 
the protective fibrous cap [1](Figure 1).  
 
The fibrous cap is an important barrier, separating the highly thrombogenic 
core from the circulating blood. However inflammation, degradative enzymes 
and cell death can compromise the cap, leading to plaque rupture [3]. Once 
the core is exposed, thrombus forms which may occlude the vessel or 
embolise, leading to ischaemic complications such as heart attacks and 
strokes. Oxidative stress, cell death and inflammation are therefore key 
processes in atherogenesis [4, 5], all of which may be caused by mtDNA 
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damage and dysfunction [6, 7]. In this review the role and mechanisms of 
mtDNA and atherosclerosis will be discussed. 
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Figure 1. Atherosclerotic plaque formation 
Circulating lipids are taken up into the vessel intima, where they become 
oxidised and promote endothelial dysfunction. Monocytes are recruited and 
become macrophages that engulf lipids to form foam cells. An inflammatory 
response is triggered, leading to cell death and the development of the plaque 
necrotic core. Vascular smooth muscle cells (VSMCs) proliferate and/or 
migrate to the intima, where they secrete the collagen and extra-cellular 
matrix that forms the protective fibrous cap. 
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Mitochondrial DNA damage and atherosclerosis 
Mitochondria are the powerhouses of the cell, responsible for generating ATP 
through oxidative phosphorylation, with ROS formed as a by-product [8]. 
Except for the nucleus mitochondria are also the only source of DNA within 
the cell. Human mtDNA exists as a 16569 bp loop, encoding 13 respiratory 
chain polypeptides, together with transfer and ribosomal RNAs [9].  
 
mtDNA is particularly vulnerable to oxidative damage, as it lies close to the 
site of ROS production and lacks protection from histones. mtDNA damage 
may also be increased in atherosclerosis as conditions that promote disease, 
such as hyperglycaemia and smoking, also increase ROS [10]. Replication 
error is another source of mtDNA defects. Mutations can occur in early life 
and become abundant through clonal expansion. It has been proposed that 
sufficient mtDNA damage can then impair respiratory chain function, and 
eventually compromise cellular function promoting ageing and disease [11]. 
 
There is now evidence that mtDNA damage is not only present but can also 
promote atherosclerosis. Early studies identified mtDNA damage in the 
aortas, hearts, and circulating leukocytes of patients with atherosclerosis [12-
14]. Furthermore, mtDNA damage is an early event in atherogenesis [14], and 
mtDNA damage and mitochondrial dysfunction were both demonstrated in a 
mouse model of atherosclerosis and metabolic syndrome [15]. Although the 
latter study suggested a causative role for mtDNA damage in atherosclerosis, 
the differing effects of mtDNA and nuclear DNA damage could not be 
distinguished [15].  
 
A useful model to examine the effects of extensive mtDNA damage is the 
mutator mouse. Polymerase gamma is the mitochondrial DNA polymerase, 
uniquely responsible for replicating the mitochondrial genome. Mutator mice 
express aspartate instead of alanine in the exonuclease domain, which 
impairs the enzyme’s proof-reading activity resulting in extensive mtDNA 
mutations [16, 17]. Mutator mice that were also deficient in apolipoprotein E 
showed that mtDNA defects promote mitochondrial dysfunction, 
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atherosclerosis and plaque vulnerability. Furthermore, mtDNA lesions were 
associated with high-risk lesions in humans [6].  
 
Collectively we now have evidence that mtDNA damage is present and 
promotes atherosclerosis, and that the findings may be relevant to human 
disease. We will now review the potential mechanisms linking mtDNA damage 
and atherosclerosis. 
 
mtDNA damage and ROS 
Harman first suggested the free radical theory of aging more than 40 years 
ago [18] . He proposed that a vicious cycle of ROS-induced mtDNA damage, 
leading to mitochondrial dysfunction and the generation of more damaging 
ROS, could lead to aging and death. The theory has been expanded to also 
include disease, and is particularly attractive when considering 
atherosclerosis where oxidative stress appears to be a key mediator. 
 
Increased ROS are present in the vessel wall at all stages of atherosclerosis, 
and can lead to modification of DNA, protein and lipids [19]. Indeed oxidative 
DNA damage has been observed in plaque VSMCs, with upregulation of the 
DNA damage response [20]. Furthermore, mitochondrial DNA damage 
precedes and correlates with plaque development [14, 21]. Lipids, too, are a 
target of ROS and lipid oxidation is well-recognised as an important event in 
atherogenesis [22].  
 
Further support for the role of ROS in atherosclerosis comes from in vivo 
models. A decrease in the antioxidant enzymes superoxide dismutase or 
glutathione peroxidase increases atherosclerosis [14, 23]. Moreover the 
expression of catalase in macrophage mitochondria has a protective effect, 
decreasing plaque formation [21].  
 
Taken together, this evidence suggests that ROS are present and have a 
causative role in atherosclerosis. However it is uncertain whether increased 
ROS are necessary to mediate the effects of mtDNA damage. When first 
described, the mutator mouse showed no increase in ROS, despite extensive 
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mtDNA defects [17, 24]. More recently, whilst increased mtDNA damage, 
atherosclerosis and plaque vulnerability were all observed, still no change in 
ROS was seen [6]. The latter study also benefited from using a novel in vivo 
ROS probe- MitoB- that is specifically targeted to the mitochondria where it 
binds to hydrogen peroxide [25]. This work therefore casts doubt on whether 
increased ROS are required to mediate the effects of mtDNA damage in aging 
and atherosclerosis.  
 
However, other work does suggest a role for ROS in the mutator mouse, with 
overexpression of mitochondria-targeted catalase attenuating cardiomyopathy 
[26]. The differing findings of these studies may be reconciled by a recent 
observation. MitoB was used to assess ROS in mutator mice, and whilst 
young mice showed no increase in ROS, aged mice did show an increase [7]. 
This would suggest that chronic, extensive mtDNA damage is necessary for 
increased ROS to occur. 
 
These findings are important when considering anti-oxidants as therapeutics, 
and may account for the lack of benefit seen so far in atherosclerosis studies. 
For example, in a mouse model, the mitochondrial targeted MitoQ ameliorated 
features of the metabolic syndrome but had no impact on atherosclerosis 
development [27]. Furthermore in humans, a meta-analysis of trials involving 
a variety of vitamins and anti-oxidants has also shown no benefit [28]. Why no 
benefit has been seen remains unclear but may be due to the timing or 
targeting of therapies. It may be that anti-oxidant therapies need to be given in 
the early stages of disease and/or for a prolonged period to be effective. The 
trials also involved systemic administration of anti-oxidants [28] but perhaps 
targeting the therapies to the specific cell types involved would be more 
beneficial. We may also need to select the appropriate patient population, as 
potentially only those who are deficient in anti-oxidants would benefit from 
treatment. 
 
The timing or targeting of therapies may explain why a beneficial effect of anti-
oxidants in human atherosclerosis is yet to be proven. An alternative 
explanation is that ROS have positive effects, which are negated by 
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antioxidants. Undoubtedly ROS can cause damaging oxidative modifications, 
but they are also involved in signalling pathways. For example, mitochondrial 
ROS may trigger a pattern of gene expression that promotes survival and 
indeed increased mitochondrial ROS production extended lifespan in a worm 
model [29, 30].  
 
Collectively, the current evidence indicates that oxidative stress is present in 
atherosclerosis, and likely promotes disease. However increased ROS are not 
necessarily required for mtDNA damage to lead to increased atherosclerosis.  
 
mtDNA damage and cell death 
MtDNA damage not only promotes oxidative stress but also regulates cell 
death, which has a key role in atherosclerosis development. Acute VSMC 
apoptosis leads to thinning of the fibrous cap, an increase of the necrotic core, 
and intimal inflammation –all features of the vulnerable lesion [31]. If VSMC 
apoptosis is chronic, increased plaque development and calcification result 
[5]. Macrophage apoptosis is also important in atherogenesis. Although 
protective in the early stage, in advanced lesions macrophage apoptosis 
causes expansion of the necrotic core [32, 33]. Furthermore, phagocytic 
clearance of apoptotic cells is impaired as plaques develop, promoting 
secondary necrosis and inflammation [34]. 
 
Mitochondria are well positioned to regulate cell death, as they are the only 
part of the cell that contains cytochrome c under normal physiological 
conditions. Cytochrome c not only forms part of the electron transport chain 
but is also a critical signal for apoptosis. Apoptotic signals converge on the 
Bcl2 proteins Bax and Bak, which oligomerise to promote mitochondrial outer 
membrane permeabilisation (MOMP). Bax and bak also activate OMA1, a 
mitochondrial inner membrane protease, that works together with MOMP to 
allow the release of cytochrome c [35]. Cytochrome c then binds to Apaf-1, 
leading to caspase activation and apoptosis execution [36](Figure 2).  
 
Mitochondria also regulate apoptosis through their dynamics [37] . The 
dynamic mitochondrial network undergoes constant fission and fusion to 
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shape mitochondrial number and mass. Mitochondrial fission accompanies 
MOMP [38], and the fission protein dynamin-related protein 1 (Drp1) 
stimulates bax oligomerisation through membrane tethering; overexpression 
of a mutated form of Drp1 delays oligomerisation and cell death [39]. Another 
regulator of apoptosis is the fusion protein optic atrophy 1 (Opa1) that is 
located on the inner mitochondrial membrane. Opa1 controls mitochondrial 
cristae shape and, by keeping the cristae junctions tight, limits cytochrome c 
release [40]. 
 
Cytochrome C release may also result from mitochondrial permeability 
transition pore (MPTP) opening. The exact composition of the MPTP remains 
debated, but cyclophilin D and ATP synthase appear to be components [41-
43]. Mitochondrial dysfunction results in conditions such as increased ROS 
and decreased mitochondrial membrane potential that promote MPTP 
opening and thus apoptosis. When the MPTP opens, equilibration of ions 
between the mitochondrial matrix and cytosol occurs. The resultant swelling 
exerts pressure on the outer membrane, leading to rupture and release of 
cytochrome c. Whilst transient MPTP opening may allow apoptosis, if 
prolonged opening occurs, collapse of oxidative phosphorylation and necrosis 
ensue [44](Figure 2).  
 
Mitochondria tightly regulate cell death, and disruption to their structure or 
function can promote apoptosis. Indeed apoptosis is seen in mutator mice, 
and is increased in VSMCs, macrophages, and plaques [6]. mtDNA damage 
therefore promotes apoptosis, and thus can promote plaque formation and 
vulnerability.  
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Figure 2. Mitochondrial regulation of cell death 
Apoptotic signals converge on the Bcl2 proteins Bax and Bak, which 
oligomerise to promote mitochondrial outer membrane permeabilisation 
(MOMP); the fission protein dynamin-related protein 1(Drp1) also stimulates 
bax oligomerisation. Bax and bak activate OMA1, a mitochondrial inner 
membrane protease, that works together with MOMP to allow the release of 
cytochrome c. Cytochrome c then binds to Apaf-1, leading to caspase 
activation and apoptosis execution. Apoptosis can be amplified by 
mitochondrial permeability transition pore (MPTP) opening, which allows entry 
of water and solutes. The resultant swelling promotes rupture and release of 
cytochrome c, but prolonged MPTP opening collapses oxidative 
phosphorylation with ensuing necrosis. Mitochondrial dysfunction leads to 
conditions that favour MPTP opening, including ATP depletion and increased 
reactive oxygen species (ROS).  
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mtDNA damage and inflammation 
Inflammation drives atherosclerosis with inflammatory cells present in both the 
plaque and the thrombus that forms upon plaque rupture. Increasingly we 
recognise that mitochondria not only generate ATP and ROS but also have a 
key role in the immune response. 
 
The innate immune response provides rapid detection and protection against 
dangerous stimuli. Toll-like receptors (TLRs) act as pattern recognition 
receptors, sensing a broad range of pathogen-associated and damage-
associated molecular patterns (PAMPs and DAMPs). Like the DNA of their 
proto bacteria predecessors, mtDNA contains significant amounts of 
unmethylated CpG islands that act as DAMPs. These inflammatory mtDNA 
motifs stimulate TLR9, leading to nuclear factor kappa beta (NFκβ) activation 
and transcription of inflammatory cytokines [45](Figure 3). Although mtDNA 
can be circulating, it may also come from damaged mitochondria that have 
escaped from autophagy [45, 46]. 
 
In addition to activating TLR9, mtDNA also elicits anti-viral immune 
responses. In the absence of mitochondrial transcription factor A (TFAM) 
mtDNA is released to the cytosol where it engages the DNA sensor cyclic 
GMP-AMP synthase (cGAS). Downstream stimulator of interferon genes 
(STING) signalling is promoted, increasing the expression of type 1 
interferons and other interferon-stimulated genes [47](Figure 3). Interestingly 
apoptotic caspase activation can attenuate this signalling pathway [48], 
demonstrating that mitochondria regulate the intertwined pathways of cell 
death and inflammation. 
 
Interferon signalling not only serves a protective anti-viral response, but is 
also implicated in atherogenesis and plaque vulnerability. The type 1 
interferons include interferon α and β (IFN α and IFNβ), which affect both 
VSMCs and macrophages. IFNα increases TNF-related apoptosis-inducing 
ligand (TRAIL) on T cells, promoting VSMC death [49]. IFNβ promotes 
macrophage-endothelial cell adhesion and leukocyte recruitment to 
atherosclerosis-prone sites. Furthermore IFNβ treatment has in vivo effects, 
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increasing plaque formation in a mouse model of atherosclerosis and indeed, 
increased type 1 IFN signalling has been confirmed in ruptured human 
plaques [50].  
 
Mitochondria regulate inflammatory cytokines through altering their 
expression and also by triggering post-translational modification and 
activation. Oxidised mtDNA binds and activates the NLRP3 inflammasome, a 
multi-protein complex composed of NLRP3, ASC and caspase 1 [51]. NLRP3 
responds to danger stimuli, including low intracellular potassium 
concentration, bacterial toxins such as nigericin, and cholesterol crystals [52]. 
Once activated, NLRP3 colocalises with its adapter protein ASC at 
perinuclear ER-mitochondrial clusters [53]. Active caspase 1 then assembles 
to cleave pro-IL1β to its mature form (Figure 3).  
 
Dysfunctional mitochondria not only activate NLRP3 through mtDNA but also 
through ROS generation [53] and cardiolipin. Although cardiolipin is usually a 
mitochondrial inner membrane lipid, it localises to the outer membrane in 
dysfunctional mitochondria. Cardiolipin can then recruit and activate NLRP3 
[54, 55]. NAD/NADH levels indicate cellular nutrient and energy status and 
can also signal danger. In mitochondrial dysfunction NAD/NADH levels fall, 
and are sensed by NAD-dependent enzymes such as the sirtuin 
deacetylases. Sirtuin 2 activity is decreased and α-tubulin accumulates, 
promoting the co-localisation of NLRP3 with ASC and therefore 
inflammasome activation [56].  
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Figure 3. Mitochondrial DNA, dysfunction and inflammation 
Mitochondria regulate inflammatory signalling, through shaping of both gene 
expression and post-translational modification. Mitochondrial DNA (mtDNA) 
contains inflammatory motifs that activate TLR9, leading to NFκβ activation 
and transcription of inflammatory cytokines such as pro-IL1β. Pro-IL1β is 
cleaved by caspase 1 to generate mature, active IL1β. Caspase 1 itself is 
regulated by the NLRP3 inflammasome, a multi-protein complex composed of 
NLRP3, ASC and pro-caspase 1. NLRP3 responds to signals generated by 
mitochondrial dysfunction- ROS, cardiolipin externalisation, and cytosolic 
mtDNA. Mt DNA also triggers interferon (IFN) expression, through engaging 
cyclic GMP-AMP synthase (cGAS) and promoting stimulator of interferon 
genes (STING) signalling. 
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mtDNA damage and dysfunction can therefore activate NLRP3 through 
mtDNA, ROS, cardiolipin and altering NAD/NADH levels. Importantly NLRP3 
inflammasome activation and increased IL1β release may promote 
atherosclerosis [52]. IL1α is also important in atherogenesis, and perhaps 
even more so than IL1β [57]. For example, transplantation of IL1α-deficient 
bone marrow into mice deficient for low-density lipoprotein receptor (LDLR) 
significantly reduces atherosclerosis. IL1α therefore induces vascular 
inflammation and its secretion, like IL1β, is regulated by mitochondrial 
function. Dietary fatty acids uncouple mitochondria, triggering a calcium flux 
that activates the calpain protease. Calpain then cleaves pro-IL1α to release 
its active, mature form [57].  
 
Taken together mitochondria are now recognised as regulators of pro-
atherogenic inflammatory signalling, through shaping of both gene expression 
and post-translational modification. In atherogenesis metabolic stressors such 
as cholesterol crystals and fatty acids may converge on mitochondria, leading 
to an inflammatory response that is amplified by underlying mtDNA damage 
and dysfunction.  
 
mtDNA damage and metabolism 
Although cell death and inflammation are important processes in 
atherogenesis, the systemic metabolic changes of diabetes, 
hypercholesterolaemia and hypertension are well-known atherosclerosis risk 
factors. We increasingly recognise that mtDNA defects not only impact upon 
mitochondrial and cellular function but whole organism metabolism [58] .	  
Mitochondria use substrates from the Krebs cycle, derived from lipids, 
carbohydrates and proteins, to generate ATP during oxidative 
phosphorylation. Mitochondria therefore have a critical role in coordinating 
metabolism and energy production. 
 
MtDNA damage is particularly associated with significant lipid changes. 
Mutator mice show loss of adipose tissue [16] and hypercholesterolaemia that 
may promote atherosclerosis [6]. The underlying mechanisms were not fully 
explored in these papers but mitochondrial dysfunction increases AMP/ATP to 
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activate AMP-activated protein kinase (AMPK) signalling. AMPK activation 
has multiple effects, including inhibition of gluconeogenesis and adipogenesis 
[59] that could lead to reduced adiposity. Alternatively, mitochondrial 
dysfunction also promotes the release of fibroblast growth factor 21 (FGF21), 
a hormone that regulates lipolysis [60-62]. Lipids are mobilised from adipose 
tissue, resulting in decreased fat mass and increased serum glycerol and free 
fatty acids [63].  
 
In addition to these systemic signalling effects on lipid metabolism, 
mitochondrial function influences cellular cholesterol transport. Macrophage 
cholesterol efflux is a step of reverse cholesterol transport, the process where 
intracellular cholesterol is returned to the liver for clearance [64]. The ATP 
binding cassette transporters ABCA1 and ABCG1 mediate cholesterol efflux 
but their ATP dependence subjects them to mitochondrial regulation. Indeed, 
inhibition of ATP synthase leads to decreased cholesterol efflux capacity, 
whilst increased mitochondrial respiration promotes cholesterol efflux and 
reduces plaque formation [65].  
 
Extensive mtDNA damage and dysfunction may therefore have multiple 
effects on lipid metabolism, including reduced cholesterol efflux, to promote 
atherosclerosis.  
 
Mitochondria as therapeutic targets in atherosclerosis 
MtDNA damage promotes increased ROS, cell death, inflammation and lipid 
changes that can all drive atherogenesis. This highlights mitochondria as 
potential therapeutic targets in atherosclerosis, and harnessing pre-existing 
protective processes may be a promising way to start. 
 
Firstly important anti-oxidant pathways are already present to protect mtDNA 
and other cellular macromolecules against the damaging effects of 
mitochondrial ROS. Matrix and inter-membrane superoxide dismutases 
convert superoxide to hydrogen peroxide, which is then safely reduced to 
water by catalase or glutathione peroxidase. Augmenting or supplementing 
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these anti-oxidant processes may reduce oxidative stress and downstream 
damage. 
 
However ROS generation may overwhelm the anti-oxidant defences, resulting 
in mtDNA damage. Countering this, mtDNA repair pathways, including base 
excision repair, mismatch repair and possibly homologous recombination [66], 
can potentially correct these defects and improve mitochondrial function. For 
example, Twinkle is a mitochondrial helicase and may have a role in mtDNA 
recombination and repair [67]. Mice over-expressing Twinkle show protection 
against ROS-induced mtDNA mutations, and improved cardiac function [68]. 
Targeting mtDNA repair may therefore be a useful pathway to protect against 
the effects of mtDNA damage. 
 
If mtDNA lesions persist despite the repair systems, mitochondrial dynamics 
may act to alleviate the damage. Mitochondrial fusion allows sharing of 
mtDNA and mitochondrial contents, protecting against mtDNA damage. 
Subsequently, when mitochondrial fusion is impaired multiple defects in 
mtDNA content, mitochondrial function and tissue function occur [69]. 
 
Mitophagy is also a key determinant of mitochondrial health when mtDNA 
damage exceeds the capacity of the protective anti-oxidant, repair, and fusion 
processes. Mitophagy is a specialised form of autophagy, where lysosomal 
degradation clears dysfunctional mitochondria from the cell, recycling 
components for further use. Dysfunctional mitochondria accumulate Pink1, 
which phosphorylates ubiquitin, parkin and mitofusin 2 [70-72]. Parkin is 
subsequently activated and ubiquinates multiple proteins, including VDAC, to 
mark mitochondria for mitophagy [73]. Although the Pink1/Parkin pathway is 
well-recognised other activation mechanisms also exist. Pink1 recruits NDP52 
and optineurin independently of Parkin to activate mitophagy [74], whilst 
BNIP3 and Nix proteins can also recruit the phagophore, and thus promote 
lysosomal fusion [75, 76]. These pathways may be useful in targeting 
mitophagy, which holds particular promise given that macrophage autophagy 
has a protective role in advanced atherosclerosis. If macrophage autophagy is 
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impaired, increased apoptosis and oxidative stress lead to increased plaque 
area and necrosis [77]. 
 
Another way to improve mitochondrial health may be through targeting the 
sirtuin family of NAD+-dependent protein deacetylases; of the 7 members, 3 
(Sirt 3 to 5) are localised to the mitochondria. The sirtuins are vital as 
metabolic sensors, matching mitochondrial function to nutrient supply [78]. 
Sirtuins regulate mitochondrial biogenesis, through sirtuin 1 deacetylation and 
regulatation of peroxisome proliferator-activated receptor gamma coactivator-
1-alpha	  (PGC1a) [79, 80]. Furthermore sirtuin 3 regulates cellular metabolism 
[81, 82], and increases oxidative phosphorylation through the deacetylation 
and activation of complexes I and II [83, 84]. ROS would of course be 
generated as a by-product, and importantly sirtuins can detoxify ROS, 
including through sirtuin 3 activation of manganese superoxide dismutase [85, 
86]. Targeting sirtuins could therefore promote changes to mitochondrial 
function, metabolism and ROS generation that could be athero-protective; 
indeed inhibition of sirtuin 1 increases atherosclerosis [87].  
 
Collectively the evidence indicates that mtDNA damage promotes multiple 
pro-atherogenic processes. Targeting mitochondria may therefore provide a 
new strategy in reducing plaque development and vulnerability. 
 
Conclusions and future  
Mitochondria exist as a dynamic network that must be able to respond to 
metabolic demands and generate ATP. Mitochondria are therefore critical for 
cellular function, yet they have kept some independence, with their own 
genome and timescale of replication. We now recognise that mitochondria 
have pivotal roles in the generation of ROS, and the regulation of cell death, 
inflammation and metabolism. mtDNA damage and mitochondrial dysfunction 
can disrupt these processes, driving plaque development and vulnerability. 
 
However important questions remain that are yet to be answered. We do not 
know whether the mtDNA damage actually seen in atherosclerosis results in 
sufficient dysfunction to be causative. Future work may also identify other 
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causes of mitochondrial dysfunction in atherosclerosis. The exact role and 
requirement for mitochondrial ROS in atherosclerosis remains debated, and 
indeed what determines whether mtDNA damage and mitochondrial 
dysfunction result in oxidative stress is unclear. Future studies may also 
identify other mechanisms linking mitochondrial dysfunction and inflammation. 
For example, does mitochondrial dysfunction lead to other pro-inflammatory 
transcriptional changes, and do mitochondria affect immune-suppressive 
signalling? Finally it is important to examine whether protecting against 
mtDNA damage and mitochondrial dysfunction can reduce atherogenesis or 
plaque vulnerability. 
 
 
 
 
Acknowledgements 
 
This work was supported by British Heart Foundation grants PG/14/69/31032 
and RG/13/14/30314, the National Institute for Health Research Cambridge 
Biomedical Research Centre, and the Academy of Medical Sciences.  
 
Disclosures: None 
 
 
  
	   21	  
References 
 
 
[1] Weber, C.; Noels, H. Atherosclerosis: current pathogenesis and 
therapeutic options. Nat Med 17:1410-1422; 2011. 
[2] Chatzizisis, Y. S.; Coskun, A. U.; Jonas, M.; Edelman, E. R.; Feldman, 
C. L.; Stone, P. H. Role of endothelial shear stress in the natural history of 
coronary atherosclerosis and vascular remodeling: molecular, cellular, and 
vascular behavior. J Am Coll Cardiol 49:2379-2393; 2007. 
[3] Weissberg, P. L. Atherogenesis: current understanding of the causes 
of atheroma. Heart 83:247-252; 2000. 
[4] Hansson, G. K.; Hermansson, A. The immune system in 
atherosclerosis. Nat Immunol 12:204-212; 2011. 
[5] Clarke, M. C.; Littlewood, T. D.; Figg, N.; Maguire, J. J.; Davenport, A. 
P.; Goddard, M.; Bennett, M. R. Chronic apoptosis of vascular smooth muscle 
cells accelerates atherosclerosis and promotes calcification and medial 
degeneration. Circ Res 102:1529-1538; 2008. 
[6] Yu, E.; Calvert, P. A.; Mercer, J. R.; Harrison, J.; Baker, L.; Figg, N. L.; 
Kumar, S.; Wang, J. C.; Hurst, L. A.; Obaid, D. R.; Logan, A.; West, N. E.; 
Clarke, M. C.; Vidal-Puig, A.; Murphy, M. P.; Bennett, M. R. Mitochondrial 
DNA damage can promote atherosclerosis independently of reactive oxygen 
species through effects on smooth muscle cells and monocytes and 
correlates with higher-risk plaques in humans. Circulation 128:702-712; 2013. 
[7] Logan, A.; Shabalina, I. G.; Prime, T. A.; Rogatti, S.; Kalinovich, A. V.; 
Hartley, R. C.; Budd, R. C.; Cannon, B.; Murphy, M. P. In vivo levels of 
	   22	  
mitochondrial hydrogen peroxide increase with age in mtDNA mutator mice. 
Aging Cell; 2014. 
[8] Turrens, J. F. Mitochondrial formation of reactive oxygen species. J 
Physiol 552:335-344; 2003. 
[9] Larsson, N. G. Somatic mitochondrial DNA mutations in mammalian 
aging. Annu Rev Biochem 79:683-706; 2010. 
[10] Du, X. L.; Edelstein, D.; Rossetti, L.; Fantus, I. G.; Goldberg, H.; 
Ziyadeh, F.; Wu, J.; Brownlee, M. Hyperglycemia-induced mitochondrial 
superoxide overproduction activates the hexosamine pathway and induces 
plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. 
Proc Natl Acad Sci U S A 97:12222-12226; 2000. 
[11] Bratic, A.; Larsson, N. G. The role of mitochondria in aging. J Clin 
Invest 123:951-957; 2013. 
[12] Botto, N.; Berti, S.; Manfredi, S.; Al-Jabri, A.; Federici, C.; Clerico, A.; 
Ciofini, E.; Biagini, A.; Andreassi, M. G. Detection of mtDNA with 4977 bp 
deletion in blood cells and atherosclerotic lesions of patients with coronary 
artery disease. Mutat Res 570:81-88; 2005. 
[13] Corral-Debrinski, M.; Shoffner, J. M.; Lott, M. T.; Wallace, D. C. 
Association of mitochondrial DNA damage with aging and coronary 
atherosclerotic heart disease. Mutat Res 275:169-180; 1992. 
[14] Ballinger, S. W.; Patterson, C.; Knight-Lozano, C. A.; Burow, D. L.; 
Conklin, C. A.; Hu, Z.; Reuf, J.; Horaist, C.; Lebovitz, R.; Hunter, G. C.; 
McIntyre, K.; Runge, M. S. Mitochondrial integrity and function in 
atherogenesis. Circulation 106:544-549; 2002. 
	   23	  
[15] Mercer, J. R.; Cheng, K. K.; Figg, N.; Gorenne, I.; Mahmoudi, M.; 
Griffin, J.; Vidal-Puig, A.; Logan, A.; Murphy, M. P.; Bennett, M. DNA damage 
links mitochondrial dysfunction to atherosclerosis and the metabolic 
syndrome. Circ Res 107:1021-1031; 2010. 
[16] Trifunovic, A.; Wredenberg, A.; Falkenberg, M.; Spelbrink, J. N.; Rovio, 
A. T.; Bruder, C. E.; Bohlooly, Y. M.; Gidlof, S.; Oldfors, A.; Wibom, R.; 
Tornell, J.; Jacobs, H. T.; Larsson, N. G. Premature ageing in mice 
expressing defective mitochondrial DNA polymerase. Nature 429:417-423; 
2004. 
[17] Kujoth, G. C.; Hiona, A.; Pugh, T. D.; Someya, S.; Panzer, K.; 
Wohlgemuth, S. E.; Hofer, T.; Seo, A. Y.; Sullivan, R.; Jobling, W. A.; Morrow, 
J. D.; Van Remmen, H.; Sedivy, J. M.; Yamasoba, T.; Tanokura, M.; 
Weindruch, R.; Leeuwenburgh, C.; Prolla, T. A. Mitochondrial DNA mutations, 
oxidative stress, and apoptosis in mammalian aging. Science 309:481-484; 
2005. 
[18] Harman, D. The biologic clock: the mitochondria? J Am Geriatr Soc 
20:145-147; 1972. 
[19] Madamanchi, N. R.; Vendrov, A.; Runge, M. S. Oxidative stress and 
vascular disease. Arterioscler Thromb Vasc Biol 25:29-38; 2005. 
[20] Gorenne, I.; Kavurma, M.; Scott, S.; Bennett, M. Vascular smooth 
muscle cell senescence in atherosclerosis. Cardiovasc Res 72:9-17; 2006. 
[21] Wang, Y.; Wang, G. Z.; Rabinovitch, P. S.; Tabas, I. Macrophage 
mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-
kappaB-mediated inflammation in macrophages. Circ Res 114:421-433; 2014. 
	   24	  
[22] Stocker, R.; Keaney, J. F., Jr. Role of oxidative modifications in 
atherosclerosis. Physiol Rev 84:1381-1478; 2004. 
[23] Torzewski, M.; Ochsenhirt, V.; Kleschyov, A. L.; Oelze, M.; Daiber, A.; 
Li, H.; Rossmann, H.; Tsimikas, S.; Reifenberg, K.; Cheng, F.; Lehr, H. A.; 
Blankenberg, S.; Forstermann, U.; Munzel, T.; Lackner, K. J. Deficiency of 
glutathione peroxidase-1 accelerates the progression of atherosclerosis in 
apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27:850-857; 
2007. 
[24] Trifunovic, A.; Hansson, A.; Wredenberg, A.; Rovio, A. T.; Dufour, E.; 
Khvorostov, I.; Spelbrink, J. N.; Wibom, R.; Jacobs, H. T.; Larsson, N. G. 
Somatic mtDNA mutations cause aging phenotypes without affecting reactive 
oxygen species production. Proc Natl Acad Sci U S A 102:17993-17998; 
2005. 
[25] Cocheme, H. M.; Logan, A.; Prime, T. A.; Abakumova, I.; Quin, C.; 
McQuaker, S. J.; Patel, J. V.; Fearnley, I. M.; James, A. M.; Porteous, C. M.; 
Smith, R. A.; Hartley, R. C.; Partridge, L.; Murphy, M. P. Using the 
mitochondria-targeted ratiometric mass spectrometry probe MitoB to measure 
H2O2 in living Drosophila. Nat Protoc 7:946-958; 2012. 
[26] Dai, D. F.; Chen, T.; Wanagat, J.; Laflamme, M.; Marcinek, D. J.; 
Emond, M. J.; Ngo, C. P.; Prolla, T. A.; Rabinovitch, P. S. Age-dependent 
cardiomyopathy in mitochondrial mutator mice is attenuated by 
overexpression of catalase targeted to mitochondria. Aging Cell 9:536-544; 
2010. 
[27] Mercer, J. R.; Yu, E.; Figg, N.; Cheng, K. K.; Prime, T. A.; Griffin, J. L.; 
Masoodi, M.; Vidal-Puig, A.; Murphy, M. P.; Bennett, M. R. The mitochondria-
	   25	  
targeted antioxidant MitoQ decreases features of the metabolic syndrome in 
ATM+/-/ApoE-/- mice. Free Radic Biol Med 52:841-849; 2012. 
[28] Myung, S. K.; Ju, W.; Cho, B.; Oh, S. W.; Park, S. M.; Koo, B. K.; Park, 
B. J.; Korean Meta-Analysis Study, G. Efficacy of vitamin and antioxidant 
supplements in prevention of cardiovascular disease: systematic review and 
meta-analysis of randomised controlled trials. Bmj 346:f10; 2013. 
[29] Yee, C.; Yang, W.; Hekimi, S. The intrinsic apoptosis pathway 
mediates the pro-longevity response to mitochondrial ROS in C. elegans. Cell 
157:897-909; 2014. 
[30] Schulz, T. J.; Zarse, K.; Voigt, A.; Urban, N.; Birringer, M.; Ristow, M. 
Glucose restriction extends Caenorhabditis elegans life span by inducing 
mitochondrial respiration and increasing oxidative stress. Cell Metab 6:280-
293; 2007. 
[31] Clarke, M. C.; Figg, N.; Maguire, J. J.; Davenport, A. P.; Goddard, M.; 
Littlewood, T. D.; Bennett, M. R. Apoptosis of vascular smooth muscle cells 
induces features of plaque vulnerability in atherosclerosis. Nat Med 12:1075-
1080; 2006. 
[32] Stoneman, V.; Braganza, D.; Figg, N.; Mercer, J.; Lang, R.; Goddard, 
M.; Bennett, M. Monocyte/macrophage suppression in CD11b diphtheria toxin 
receptor transgenic mice differentially affects atherogenesis and established 
plaques. Circ Res 100:884-893; 2007. 
[33] Thorp, E.; Li, Y.; Bao, L.; Yao, P. M.; Kuriakose, G.; Rong, J.; Fisher, 
E. A.; Tabas, I. Brief report: increased apoptosis in advanced atherosclerotic 
lesions of Apoe-/- mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc 
Biol 29:169-172; 2009. 
	   26	  
[34] Schrijvers, D. M.; De Meyer, G. R.; Kockx, M. M.; Herman, A. G.; 
Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in 
atherosclerosis. Arterioscler Thromb Vasc Biol 25:1256-1261; 2005. 
[35] Jiang, X.; Jiang, H.; Shen, Z.; Wang, X. Activation of mitochondrial 
protease OMA1 by Bax and Bak promotes cytochrome c release during 
apoptosis. Proc Natl Acad Sci U S A 111:14782-14787; 2014. 
[36] Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; 
Alnemri, E. S.; Wang, X. Cytochrome c and dATP-dependent formation of 
Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 
91:479-489; 1997. 
[37] Friedman, J. R.; Nunnari, J. Mitochondrial form and function. Nature 
505:335-343; 2014. 
[38] Ishihara, N.; Nomura, M.; Jofuku, A.; Kato, H.; Suzuki, S. O.; Masuda, 
K.; Otera, H.; Nakanishi, Y.; Nonaka, I.; Goto, Y.; Taguchi, N.; Morinaga, H.; 
Maeda, M.; Takayanagi, R.; Yokota, S.; Mihara, K. Mitochondrial fission factor 
Drp1 is essential for embryonic development and synapse formation in mice. 
Nat Cell Biol 11:958-966; 2009. 
[39] Montessuit, S.; Somasekharan, S. P.; Terrones, O.; Lucken-
Ardjomande, S.; Herzig, S.; Schwarzenbacher, R.; Manstein, D. J.; Bossy-
Wetzel, E.; Basanez, G.; Meda, P.; Martinou, J. C. Membrane remodeling 
induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. 
Cell 142:889-901; 2010. 
[40] Frezza, C.; Cipolat, S.; Martins de Brito, O.; Micaroni, M.; 
Beznoussenko, G. V.; Rudka, T.; Bartoli, D.; Polishuck, R. S.; Danial, N. N.; 
	   27	  
De Strooper, B.; Scorrano, L. OPA1 controls apoptotic cristae remodeling 
independently from mitochondrial fusion. Cell 126:177-189; 2006. 
[41] Alavian, K. N.; Beutner, G.; Lazrove, E.; Sacchetti, S.; Park, H. A.; 
Licznerski, P.; Li, H.; Nabili, P.; Hockensmith, K.; Graham, M.; Porter, G. A., 
Jr.; Jonas, E. A. An uncoupling channel within the c-subunit ring of the F1FO 
ATP synthase is the mitochondrial permeability transition pore. Proc Natl 
Acad Sci U S A 111:10580-10585; 2014. 
[42] Kwong, J. Q.; Molkentin, J. D. Physiological and pathological roles of 
the mitochondrial permeability transition pore in the heart. Cell Metab 21:206-
214; 2015. 
[43] Giorgio, V.; von Stockum, S.; Antoniel, M.; Fabbro, A.; Fogolari, F.; 
Forte, M.; Glick, G. D.; Petronilli, V.; Zoratti, M.; Szabo, I.; Lippe, G.; Bernardi, 
P. Dimers of mitochondrial ATP synthase form the permeability transition 
pore. Proc Natl Acad Sci U S A 110:5887-5892; 2013. 
[44] Halestrap, A. P.; Clarke, S. J.; Javadov, S. A. Mitochondrial 
permeability transition pore opening during myocardial reperfusion--a target 
for cardioprotection. Cardiovasc Res 61:372-385; 2004. 
[45] Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, 
K.; Itagaki, K.; Hauser, C. J. Circulating mitochondrial DAMPs cause 
inflammatory responses to injury. Nature 464:104-107; 2010. 
[46] Oka, T.; Hikoso, S.; Yamaguchi, O.; Taneike, M.; Takeda, T.; Tamai, 
T.; Oyabu, J.; Murakawa, T.; Nakayama, H.; Nishida, K.; Akira, S.; 
Yamamoto, A.; Komuro, I.; Otsu, K. Mitochondrial DNA that escapes from 
autophagy causes inflammation and heart failure. Nature 485:251-255; 2012. 
	   28	  
[47] West, A. P.; Khoury-Hanold, W.; Staron, M.; Tal, M. C.; Pineda, C. M.; 
Lang, S. M.; Bestwick, M.; Duguay, B. A.; Raimundo, N.; MacDuff, D. A.; 
Kaech, S. M.; Smiley, J. R.; Means, R. E.; Iwasaki, A.; Shadel, G. S. 
Mitochondrial DNA stress primes the antiviral innate immune response. 
Nature 520:553-557; 2015. 
[48] White, M. J.; McArthur, K.; Metcalf, D.; Lane, R. M.; Cambier, J. C.; 
Herold, M. J.; van Delft, M. F.; Bedoui, S.; Lessene, G.; Ritchie, M. E.; Huang, 
D. C.; Kile, B. T. Apoptotic caspases suppress mtDNA-induced STING-
mediated type I IFN production. Cell 159:1549-1562; 2014. 
[49] Niessner, A.; Sato, K.; Chaikof, E. L.; Colmegna, I.; Goronzy, J. J.; 
Weyand, C. M. Pathogen-sensing plasmacytoid dendritic cells stimulate 
cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. 
Circulation 114:2482-2489; 2006. 
[50] Goossens, P.; Gijbels, M. J.; Zernecke, A.; Eijgelaar, W.; Vergouwe, M. 
N.; van der Made, I.; Vanderlocht, J.; Beckers, L.; Buurman, W. A.; Daemen, 
M. J.; Kalinke, U.; Weber, C.; Lutgens, E.; de Winther, M. P. Myeloid type I 
interferon signaling promotes atherosclerosis by stimulating macrophage 
recruitment to lesions. Cell Metab 12:142-153; 2010. 
[51] Shimada, K.; Crother, T. R.; Karlin, J.; Dagvadorj, J.; Chiba, N.; Chen, 
S.; Ramanujan, V. K.; Wolf, A. J.; Vergnes, L.; Ojcius, D. M.; Rentsendorj, A.; 
Vargas, M.; Guerrero, C.; Wang, Y.; Fitzgerald, K. A.; Underhill, D. M.; Town, 
T.; Arditi, M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome 
during apoptosis. Immunity 36:401-414; 2012. 
[52] Duewell, P.; Kono, H.; Rayner, K. J.; Sirois, C. M.; Vladimer, G.; 
Bauernfeind, F. G.; Abela, G. S.; Franchi, L.; Nunez, G.; Schnurr, M.; Espevik, 
	   29	  
T.; Lien, E.; Fitzgerald, K. A.; Rock, K. L.; Moore, K. J.; Wright, S. D.; 
Hornung, V.; Latz, E. NLRP3 inflammasomes are required for atherogenesis 
and activated by cholesterol crystals. Nature 464:1357-1361; 2010. 
[53] Zhou, R.; Yazdi, A. S.; Menu, P.; Tschopp, J. A role for mitochondria in 
NLRP3 inflammasome activation. Nature 469:221-225; 2011. 
[54] Iyer, S. S.; He, Q.; Janczy, J. R.; Elliott, E. I.; Zhong, Z.; Olivier, A. K.; 
Sadler, J. J.; Knepper-Adrian, V.; Han, R.; Qiao, L.; Eisenbarth, S. C.; 
Nauseef, W. M.; Cassel, S. L.; Sutterwala, F. S. Mitochondrial cardiolipin is 
required for Nlrp3 inflammasome activation. Immunity 39:311-323; 2013. 
[55] Chu, C. T.; Ji, J.; Dagda, R. K.; Jiang, J. F.; Tyurina, Y. Y.; Kapralov, A. 
A.; Tyurin, V. A.; Yanamala, N.; Shrivastava, I. H.; Mohammadyani, D.; Qiang 
Wang, K. Z.; Zhu, J.; Klein-Seetharaman, J.; Balasubramanian, K.; Amoscato, 
A. A.; Borisenko, G.; Huang, Z.; Gusdon, A. M.; Cheikhi, A.; Steer, E. K.; 
Wang, R.; Baty, C.; Watkins, S.; Bahar, I.; Bayir, H.; Kagan, V. E. Cardiolipin 
externalization to the outer mitochondrial membrane acts as an elimination 
signal for mitophagy in neuronal cells. Nat Cell Biol 15:1197-1205; 2013. 
[56] Misawa, T.; Takahama, M.; Kozaki, T.; Lee, H.; Zou, J.; Saitoh, T.; 
Akira, S. Microtubule-driven spatial arrangement of mitochondria promotes 
activation of the NLRP3 inflammasome. Nat Immunol 14:454-460; 2013. 
[57] Freigang, S.; Ampenberger, F.; Weiss, A.; Kanneganti, T. D.; Iwakura, 
Y.; Hersberger, M.; Kopf, M. Fatty acid-induced mitochondrial uncoupling 
elicits inflammasome-independent IL-1alpha and sterile vascular inflammation 
in atherosclerosis. Nat Immunol 14:1045-1053; 2013. 
[58] Nunnari, J.; Suomalainen, A. Mitochondria: in sickness and in health. 
Cell 148:1145-1159; 2012. 
	   30	  
[59] Hardie, D. G.; Ross, F. A.; Hawley, S. A. AMPK: a nutrient and energy 
sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251-262; 
2012. 
[60] Hotta, Y.; Nakamura, H.; Konishi, M.; Murata, Y.; Takagi, H.; 
Matsumura, S.; Inoue, K.; Fushiki, T.; Itoh, N. Fibroblast growth factor 21 
regulates lipolysis in white adipose tissue but is not required for ketogenesis 
and triglyceride clearance in liver. Endocrinology 150:4625-4633; 2009. 
[61] Tyynismaa, H.; Carroll, C. J.; Raimundo, N.; Ahola-Erkkila, S.; Wenz, 
T.; Ruhanen, H.; Guse, K.; Hemminki, A.; Peltola-Mjosund, K. E.; Tulkki, V.; 
Oresic, M.; Moraes, C. T.; Pietilainen, K.; Hovatta, I.; Suomalainen, A. 
Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 
19:3948-3958; 2010. 
[62] Suomalainen, A.; Elo, J. M.; Pietilainen, K. H.; Hakonen, A. H.; 
Sevastianova, K.; Korpela, M.; Isohanni, P.; Marjavaara, S. K.; Tyni, T.; Kiuru-
Enari, S.; Pihko, H.; Darin, N.; Ounap, K.; Kluijtmans, L. A.; Paetau, A.; 
Buzkova, J.; Bindoff, L. A.; Annunen-Rasila, J.; Uusimaa, J.; Rissanen, A.; 
Yki-Jarvinen, H.; Hirano, M.; Tulinius, M.; Smeitink, J.; Tyynismaa, H. FGF-21 
as a biomarker for muscle-manifesting mitochondrial respiratory chain 
deficiencies: a diagnostic study. Lancet neurology 10:806-818; 2011. 
[63] Kim, K. H.; Jeong, Y. T.; Oh, H.; Kim, S. H.; Cho, J. M.; Kim, Y. N.; 
Kim, S. S.; Kim do, H.; Hur, K. Y.; Kim, H. K.; Ko, T.; Han, J.; Kim, H. L.; Kim, 
J.; Back, S. H.; Komatsu, M.; Chen, H.; Chan, D. C.; Konishi, M.; Itoh, N.; 
Choi, C. S.; Lee, M. S. Autophagy deficiency leads to protection from obesity 
and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 19:83-92; 
2013. 
	   31	  
[64] Cuchel, M.; Rader, D. J. Macrophage reverse cholesterol transport: key 
to the regression of atherosclerosis? Circulation 113:2548-2555; 2006. 
[65] Karunakaran, D.; Thrush, A. B.; Nguyen, M. A.; Richards, L.; Geoffrion, 
M.; Singaravelu, R.; Ramphos, E.; Shangari, P.; Ouimet, M.; Pezacki, J. P.; 
Moore, K. J.; Perisic, L.; Maegdefessel, L.; Hedin, U.; Harper, M. E.; Rayner, 
K. J. Macrophage Mitochondrial Energy Status Regulates Cholesterol Efflux 
and Is Enhanced by Anti-miR33 in Atherosclerosis. Circ Res 117:266-278; 
2015. 
[66] Kazak, L.; Reyes, A.; Holt, I. J. Minimizing the damage: repair 
pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 13:659-671; 
2012. 
[67] Pohjoismaki, J. L.; Goffart, S.; Tyynismaa, H.; Willcox, S.; Ide, T.; 
Kang, D.; Suomalainen, A.; Karhunen, P. J.; Griffith, J. D.; Holt, I. J.; Jacobs, 
H. T. Human heart mitochondrial DNA is organized in complex catenated 
networks containing abundant four-way junctions and replication forks. J Biol 
Chem 284:21446-21457; 2009. 
[68] Pohjoismaki, J. L.; Williams, S. L.; Boettger, T.; Goffart, S.; Kim, J.; 
Suomalainen, A.; Moraes, C. T.; Braun, T. Overexpression of Twinkle-
helicase protects cardiomyocytes from genotoxic stress caused by reactive 
oxygen species. Proc Natl Acad Sci U S A 110:19408-19413; 2013. 
[69] Chen, H.; Vermulst, M.; Wang, Y. E.; Chomyn, A.; Prolla, T. A.; 
McCaffery, J. M.; Chan, D. C. Mitochondrial fusion is required for mtDNA 
stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141:280-
289; 2010. 
	   32	  
[70] Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D. F.; Gautier, C. A.; 
Shen, J.; Cookson, M. R.; Youle, R. J. PINK1 is selectively stabilized on 
impaired mitochondria to activate Parkin. PLoS biology 8:e1000298; 2010. 
[71] Chen, Y.; Dorn, G. W., 2nd. PINK1-phosphorylated mitofusin 2 is a 
Parkin receptor for culling damaged mitochondria. Science 340:471-475; 
2013. 
[72] Koyano, F.; Okatsu, K.; Kosako, H.; Tamura, Y.; Go, E.; Kimura, M.; 
Kimura, Y.; Tsuchiya, H.; Yoshihara, H.; Hirokawa, T.; Endo, T.; Fon, E. A.; 
Trempe, J. F.; Saeki, Y.; Tanaka, K.; Matsuda, N. Ubiquitin is phosphorylated 
by PINK1 to activate parkin. Nature 510:162-166; 2014. 
[73] Geisler, S.; Holmstrom, K. M.; Skujat, D.; Fiesel, F. C.; Rothfuss, O. C.; 
Kahle, P. J.; Springer, W. PINK1/Parkin-mediated mitophagy is dependent on 
VDAC1 and p62/SQSTM1. Nat Cell Biol 12:119-131; 2010. 
[74] Lazarou, M.; Sliter, D. A.; Kane, L. A.; Sarraf, S. A.; Wang, C.; Burman, 
J. L.; Sideris, D. P.; Fogel, A. I.; Youle, R. J. The ubiquitin kinase PINK1 
recruits autophagy receptors to induce mitophagy. Nature 524:309-314; 2015. 
[75] Rikka, S.; Quinsay, M. N.; Thomas, R. L.; Kubli, D. A.; Zhang, X.; 
Murphy, A. N.; Gustafsson, A. B. Bnip3 impairs mitochondrial bioenergetics 
and stimulates mitochondrial turnover. Cell death and differentiation 18:721-
731; 2011. 
[76] Novak, I.; Kirkin, V.; McEwan, D. G.; Zhang, J.; Wild, P.; Rozenknop, 
A.; Rogov, V.; Lohr, F.; Popovic, D.; Occhipinti, A.; Reichert, A. S.; Terzic, J.; 
Dotsch, V.; Ney, P. A.; Dikic, I. Nix is a selective autophagy receptor for 
mitochondrial clearance. EMBO reports 11:45-51; 2010. 
	   33	  
[77] Liao, X.; Sluimer, J. C.; Wang, Y.; Subramanian, M.; Brown, K.; 
Pattison, J. S.; Robbins, J.; Martinez, J.; Tabas, I. Macrophage autophagy 
plays a protective role in advanced atherosclerosis. Cell Metab 15:545-553; 
2012. 
[78] Sack, M. N.; Finkel, T. Mitochondrial metabolism, sirtuins, and aging. 
Cold Spring Harbor perspectives in biology 4; 2012. 
[79] Rodgers, J. T.; Lerin, C.; Haas, W.; Gygi, S. P.; Spiegelman, B. M.; 
Puigserver, P. Nutrient control of glucose homeostasis through a complex of 
PGC-1alpha and SIRT1. Nature 434:113-118; 2005. 
[80] Nemoto, S.; Fergusson, M. M.; Finkel, T. SIRT1 functionally interacts 
with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J 
Biol Chem 280:16456-16460; 2005. 
[81] Hirschey, M. D.; Shimazu, T.; Goetzman, E.; Jing, E.; Schwer, B.; 
Lombard, D. B.; Grueter, C. A.; Harris, C.; Biddinger, S.; Ilkayeva, O. R.; 
Stevens, R. D.; Li, Y.; Saha, A. K.; Ruderman, N. B.; Bain, J. R.; Newgard, C. 
B.; Farese, R. V., Jr.; Alt, F. W.; Kahn, C. R.; Verdin, E. SIRT3 regulates 
mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 
464:121-125; 2010. 
[82] Schlicker, C.; Gertz, M.; Papatheodorou, P.; Kachholz, B.; Becker, C. 
F.; Steegborn, C. Substrates and regulation mechanisms for the human 
mitochondrial sirtuins Sirt3 and Sirt5. Journal of molecular biology 382:790-
801; 2008. 
[83] Ahn, B. H.; Kim, H. S.; Song, S.; Lee, I. H.; Liu, J.; Vassilopoulos, A.; 
Deng, C. X.; Finkel, T. A role for the mitochondrial deacetylase Sirt3 in 
	   34	  
regulating energy homeostasis. Proc Natl Acad Sci U S A 105:14447-14452; 
2008. 
[84] Cimen, H.; Han, M. J.; Yang, Y.; Tong, Q.; Koc, H.; Koc, E. C. 
Regulation of succinate dehydrogenase activity by SIRT3 in mammalian 
mitochondria. Biochemistry 49:304-311; 2010. 
[85] Qiu, X.; Brown, K.; Hirschey, M. D.; Verdin, E.; Chen, D. Calorie 
restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell 
Metab 12:662-667; 2010. 
[86] Chen, Y.; Zhang, J.; Lin, Y.; Lei, Q.; Guan, K. L.; Zhao, S.; Xiong, Y. 
Tumour suppressor SIRT3 deacetylates and activates manganese superoxide 
dismutase to scavenge ROS. EMBO reports 12:534-541; 2011. 
[87] Gorenne, I.; Kumar, S.; Gray, K.; Figg, N.; Yu, H.; Mercer, J.; Bennett, 
M. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and 
inhibits atherosclerosis. Circulation 127:386-396; 2013. 
 
